Manara - Qatar Research Repository
Browse
1/1
2 files

Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life

Version 2 2023-10-19, 11:44
Version 1 2023-06-19, 11:41
journal contribution
revised on 2023-10-19, 11:41 and posted on 2023-10-19, 11:44 authored by Rasha Kaddoura, Daoud Al-Badriyeh, Dina Abushanab, Mohammed Al-Hijji

Many questions were raised due to the divergent results between COAPT and MITRA-FR trials on the use of percutaneous mitral valve repair (PMVr) for secondary mitral regurgitation (SMR). This paper examined pooled patients’ characteristics and outcomes from real-life experience compared with those in the two landmark trials. A comprehensive search identified eligible studies published in 2020 and 2021. Mean difference and odds ratio (OR) were used to compare continuous and categorical data. Thirty-three studies included more than 9200 patients. Patients in landmark trials were younger than in real-life, less likely to present with severe heart failure symptoms [(COAPT: OR 0.25; 95% CI: 0.21, 0.31); (MITRA-FR: OR 0.32; 95% CI: 0.23, 0.45)] or severe MR grade (COAPT only: OR 0.57; 95% CI: 0.45, 0.71) with larger left ventricular end diastolic volume. Procedure success (OR 1.94; 95% CI: 1.10, 3.40) was more frequent with lower all-cause mortality (OR 0.73; 95% CI: 0.54, 0.99) in COAPT. Real-life patients experienced more favorable procedural and clinical outcomes compared with MITRA-FR patients. Real-life data on PMVr in SMR showed important variations in patient selection and procedural outcomes. Rates of death and heart failure hospitalization in observational studies were lower than MITRA-FR but higher than COAPT trial.

Other Information

Published in: Current Problems in Cardiology
License: http://creativecommons.org/licenses/by/4.0/
See article on publisher's website: http://dx.doi.org/10.1016/j.cpcardiol.2023.101889

Funding

Open Access funding provided by the Qatar National Library

History

Language

  • English

Publisher

Elsevier

Publication Year

  • 2023

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License

Institution affiliated with

  • Hamad Medical Corporation
  • Heart Hospital - HMC
  • Qatar University
  • Qatar University Health - QU
  • College of Pharmacy - QU HEALTH